about
Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patientsCALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosisCHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapyCALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisonsLenalidomide therapy in myelofibrosis with myeloid metaplasia.Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature.A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapieCSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)Development of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partnersC-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes.Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma.Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death.Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphomaThe oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system.Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.How precisely can data from transgenic mouse mutation-detection systems be extrapolated to humans?: lesions from the human factor IX gene.Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 RearrangementsSF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic valueIsolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance.Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myelomaAn MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome.A novel report of cig-FISH and cytogenetics in POEMS syndrome.Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
P50
Q24532183-591E986C-D96A-48ED-AFED-34BE1A761A41Q27852820-C6239EE4-3E38-4800-AC73-EF944EA301E1Q27853043-ED745852-F620-4763-B6AD-16131EFF0D49Q28184867-C3E1BBD0-5BD8-47D3-8D85-3974727F1127Q29998841-C380FDFB-CBC2-4AA0-A44D-5AF5D4120404Q33370821-68E7419C-299E-47AE-A3CA-170B5791BE70Q33415134-16A2D78C-5F57-4CA8-89DC-D52AB34A436AQ33419399-9B2A6201-DD67-42E8-94B3-C19D07D64146Q33504464-E2BF57A7-F23E-4D80-9A3F-E98BEADDA7E5Q33600822-B710A006-CF40-4AE8-AC14-B55CCB036EC4Q33600826-7CF921C0-C5CE-4830-A718-B2496EF01FCAQ33884167-65FDDBA8-96AD-4F15-B79B-29F0B97179CDQ33909621-3D73CFE0-C14D-4B41-91C5-CB0B5C22B2B5Q34106853-37769F4F-D9DA-46E4-92D4-448366729E04Q34362370-A4A2CB47-1917-424A-B4EB-296DB0138417Q34570939-4DF7865A-AFB6-49C2-8A9A-A7237B9D877FQ34612782-9F276594-957D-469A-8A7D-8D34C2178BE9Q34620470-9D1EB8BC-9EF6-4CD7-97E0-D6E9F464797CQ34667820-21919BC6-87B9-40A6-826A-C1BD9743FE34Q35168115-2F6966E2-D292-446A-84AB-BAB0F8D63AABQ35238670-04063123-CB33-4EF7-8992-E6F45FDCD2D9Q35579434-981DE625-1657-46CA-A8C6-C9B76AEB974DQ35593893-A9150153-9011-49BD-A6C6-D75764AD9F24Q35607281-01613CEA-D282-44D0-8B7E-5DF3AE117CE4Q35789621-1E166319-D246-414F-A590-B9F65CE97A2CQ35847679-1FC0B3AF-E1B0-48C5-AA80-32BAACC24535Q36022544-67AC3634-345A-42FC-8452-F7DF38285100Q36163066-D03430A1-1AF7-4D30-B755-7E81B6185BB4Q36220730-2A9EB02C-592A-4014-AB24-98D3D191A9C5Q36674814-F284DD7D-F286-4AC1-86FE-F0486EA0BDECQ36692756-11B41498-EA16-4748-949E-E5C72B9ECA75Q36754816-1239567B-71CA-4F6A-8A20-F08AF4BEBE02Q36807290-80A1035A-2A82-45C4-81B4-8A37B60023D6Q37027772-466F8266-3644-4402-BB55-6013166238E4Q37088691-4B7E0CFD-E000-4C60-AEA9-40183FB9B587Q37112885-2F63B735-001F-44AC-8EEA-FCFCD64A6053Q37146231-71110B37-EB99-4AA8-9F80-3984AFBA7B7FQ37401608-030B7FC9-B88F-49EE-A34C-E3853FEDA7F1Q37641596-8CA436B4-1B17-43DD-9431-C2330B70A5E9Q37702336-0F4C0ACE-62CC-4630-A36D-89C92C77B2E1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rhett P Ketterling
@es
Rhett P. Ketterling
@en
Rhett P. Ketterling
@nl
Rhett P. Ketterling
@sl
type
label
Rhett P Ketterling
@es
Rhett P. Ketterling
@en
Rhett P. Ketterling
@nl
Rhett P. Ketterling
@sl
prefLabel
Rhett P Ketterling
@es
Rhett P. Ketterling
@en
Rhett P. Ketterling
@nl
Rhett P. Ketterling
@sl
P106
P108
P1153
7004640443
P21
P31
P496
0000-0001-6479-7897
P569
2000-01-01T00:00:00Z